Bristol-Myers, H. Lee Moffitt Cancer Center deal

The center and Bristol-Myers Squibb partnered as part of BMS’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program to investigate immuno-oncology therapeutics for patients with high-risk, poo...